2019
DOI: 10.3389/fgene.2019.00570
|View full text |Cite
|
Sign up to set email alerts
|

Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis

Abstract: Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects about 1% of the world’s population. The etiology of RA remains unknown. It is considered to occur in the presence of genetic and environmental factors. An increasing body of evidence pinpoints that epigenetic modifications play an important role in the regulation of RA pathogenesis. Epigenetics causes heritable phenotype changes that are not determined by changes in the DNA sequence. The major epigenetic mechanisms include DNA methylation,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
90
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 118 publications
(98 citation statements)
references
References 112 publications
0
90
0
1
Order By: Relevance
“…Recently, the results of a GWAS—a study aimed to determine personalised RA therapy based on the genetic polymorphisms associated with sensitivity to FDA-approved antirheumatic drugs—have been published. Moreover, epigenetic changes (including microRNA polymorphism and expression) altering the disease complication risk and response to treatment should be taken to account, along with the germline variants assessment for RA predisposition and therapy response [ 96 , 97 ]. In that way, researchers are striving to develop a genetic testing algorithm for DMARD therapy personalisation to make RA treatment more clinically- and cost-effective.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, the results of a GWAS—a study aimed to determine personalised RA therapy based on the genetic polymorphisms associated with sensitivity to FDA-approved antirheumatic drugs—have been published. Moreover, epigenetic changes (including microRNA polymorphism and expression) altering the disease complication risk and response to treatment should be taken to account, along with the germline variants assessment for RA predisposition and therapy response [ 96 , 97 ]. In that way, researchers are striving to develop a genetic testing algorithm for DMARD therapy personalisation to make RA treatment more clinically- and cost-effective.…”
Section: Discussionmentioning
confidence: 99%
“…It is also possible to induce demethylation of methylated cytosine (5mC) at CpG sites and revert histone modifications [119]. At the same time, it is hardly conceivable to identify a sole target for RA treatment, because multiple epigenetic factors acting in distinct cells are collectively involved in the pathogenesis and progression of the disease [4]. To the best of our knowledge, there have been no experimental studies on RA treatment via genome or epigenome editing.…”
Section: (Epi)genome Editingmentioning
confidence: 99%
“…Rheumatoid arthritis (RA) is an autoimmune disease that affects about 1% of the world's population [2,3]. The main problem in RA treatment is that the exact causes of the disease are unknown [4]. Obviously, a genetic predisposition is among the major factors, because the prevalence varies in different populations.…”
Section: Introductionmentioning
confidence: 99%
“…There is a clear genetic basis to RA but its underlying mechanisms remain unknown (9). Recently, an increasing number of studies have attempted to reveal the important role of epigenetics in the pathogenesis of RA (10,11). Circular RNAs (circRNAs) and long non-coding RNA (lncRNA), a novel type of endogenous non-coding RNA recently rediscovered (12,13), are known to modulate the activity of interacting proteins or act as miRNA sponges.…”
Section: Introductionmentioning
confidence: 99%